| Metric | Value (₹ Cr) | Q3 FY26 | Q4 FY25 |
|---|---|---|---|
| Revenue | 2.3K | 7.9% | 18.7% |
| Total Income | 2.3K | 8.0% | 19.2% |
| Expenditure | 2.1K | 5.7% | 22.7% |
| PBT | 176.00 | 88.2% | 14.6% |
| Net Profit | 119.30 | 113.8% | 21.1% |
| OPM | 14.22% | 2.45pp | 3.52pp |
| NPM | 5.16% | 2.56pp | 2.64pp |
| EPS | 7.55 | 114.5% | 22.3% |
Jubilant Pharmova FY26 Revenue Up 14% to ₹8,280 Cr
22 May 2026 · 22 May, 2:54 pm
Summary
Jubilant Pharmova Limited announced robust financial results for Q4 and the full year ended March 31, 2026, showcasing solid revenue growth across all business segments. For FY26, revenue surged by 14% year-over-year to ₹8,280 crore, with Q4'FY26 revenue climbing 19% to ₹2,290 crore. The company achieved an 8% increase in full-year EBITDA, reaching ₹1,326 crore, and a 7% rise in Normalised PAT to ₹442 crore, primarily due to improved operating performance. Management expressed confidence in strengthening growth momentum and anticipates improved EBITDA margins from H2'FY27, driven by the stabilization of production at its Montreal facility and continuous strategic investments.
Key Highlights
- 1
Jubilant Pharmova reported a strong 14% year-over-year revenue growth for FY26, reaching ₹8,280 crore.
- 2
Q4'FY26 revenue increased by 19% year-over-year to ₹2,290 crore, driven by growth across Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, and Generics segments.
- 3
Full-year FY26 EBITDA grew by 8% to ₹1,326 crore, and Normalised PAT saw a 7% increase, totaling ₹442 crore.
- 4
The company onboarded one of the world's largest Oncology products on its CDMO Sterile Injectables Spokane Line 3.
- 5
The Board has proposed a dividend of ₹5 per equity share for the financial year ended March 31, 2026.
- 6
Net Debt / EBITDA remained range bound at 1.3x in March 2026, slightly up from 1.1x in March 2025, due to strategic investments for future growth.
- 7
Management anticipates EBITDA margins to strengthen from H2'FY27 onwards following the stabilization of production at the Montreal facility.
Management Comments
Mr. Shyam S Bhartia and Mr. Hari S Bhartia
We are pleased to announce revenue of Rs. 8,280 Cr. for FY26, which reflects a solid growth of 14% on YoY basis. Revenue growth is particularly driven by incremental revenue generation from the new & third line in CDMO Sterile Injectable business. We expect this growth momentum to strengthen as we move in the next financial year. EBITDA for the year grew by 8% to Rs.1,326 Cr. due to improved performance across all segments except Radiopharmaceuticals, which was affected due to lower production of SPECT products at CMO Montreal. Normalised PAT for the year grew by 7% to Rs. 442 Cr. due to improved operating performance of the business. As we are consciously investing in businesses to secure future growth, Net Debt / EBITDA remains range bound at 1.3x in Mar’26, as compared to 1.1x in Mar’25. During FY26, we saw exceptional growth momentum in the Ruby-Fill® installs. In the Allergy Immunotherapy business, we witnessed increase in demand from both markets, US and Outside US. In the CDMO Sterile Injectables business, we saw one of the fastest revenue ramp up across the industry, at Line 3 in Spokane. We are proud to share that we have onboarded one of the World’s largest Oncology products on our Line 3. In the CRDMO business, we announced a strategic partnership with Pierre Fabre, France, to expand our footprint in Europe in areas such as biologics (mAbs) and Antibody-Drug Conjugates (ADCs). We also combined drug discovery business and API Business in a single entity to improve operational efficiency & increase the brand recall of the business. In the Generics Business, we delivered a year of strong growth and double digit operating profitability. Lastly, in our Proprietary Novel drugs business, we continue to make progress in JBI-802 and JBI-778 clinical trials. During the year, particularly in the second half, we witnessed a decline in EBITDA margins, primarily due to the temporary shutdown of our CDMO Sterile Injectables facility in Montreal, for remediation, following FDA observations. We anticipate EBITDA margins to strengthen from H2’FY27 onwards post stabilisation of production at Montreal, effectively offsetting higher depreciation costs and driving net profit growth.
Informational and educational content only. Not investment advice.